Comp Set ADVENZYMES AARTIPHARM× AARTIDRUGS× AGARWALEYE× + AKUMS + ALIVUS + APLLTD + CORONA + HCG + JLHL + MARKSANS + METROPOLIS + PARKHOSPS
In ₹ Crore except Per Share
Latest Annual
ADVENZYMES
FY26
AARTIPHARM
FY26
AARTIDRUGS
FY26
AGARWALEYE
FY26
Peer
Average
Valuation — at last close P/E ◆ 17.52×48.14× 21.02× 116.08× 61.75× -72% P/B ◆ 1.81×3.96× 2.65× 7.64× 4.75× -62% EV/EBITDA ◆ 10.16×24.61× 15.09× 27.13× 22.27× -54% Market Cap ₹2,956 Cr ₹8,410 Cr ₹4,098 Cr ₹15,482 Cr ₹9,330 Cr -68% Growth Revenue CAGR 3Y ◆ 11.32%-2.20% -1.89% — -2.04% +654% Revenue CAGR 5Y ◆ 8.24%— 3.55% — 3.55% +132% Net Income CAGR 3Y ◆ 18.68%-3.35% 5.43% — 1.04% +1696% Revenue YoY (latest Q) 2.08% ◆ 45.92%19.01% 25.97% 30.30% -93% Net Income YoY (latest Q) -4.58% ◆ 155.96%-7.12% 44.56% 64.47% -107% Profitability EBITDA Margin ◆ 30.72%20.29% 12.05% 27.38% 19.91% +54% Net Income Margin ◆ 23.28%9.60% 7.60% 8.08% 8.43% +176% Return on Common Equity 11.05% 8.40% ◆ 13.36%6.84% 9.53% +16% Return on Capital Employed 11.61% 11.05% ◆ 13.34%8.79% 11.06% +5% Return on Assets ◆ 10.03%5.47% 7.23% 4.42% 5.71% +76% Credit & Quality Total Debt/Equity ◆ 0.01×0.32× 0.37× 0.07× 0.25× -96% Interest Coverage ◆ 71.91×5.65× 7.19× 3.24× 5.36× +1242% Scale — latest FY Revenue / Total Income ₹746 Cr ₹1,819 Cr ₹2,565 Cr ₹2,080 Cr ₹2,155 Cr -65% Net Income ₹174 Cr ₹175 Cr ₹195 Cr ₹168 Cr ₹179 Cr -3% Total Assets ₹1,839 Cr ₹3,482 Cr ₹2,815 Cr ₹3,942 Cr ₹3,413 Cr -46% EPS ₹15.08 ₹19.27 ₹21.36 ₹4.21 ₹14.95 +1% Book Value per Share ₹145.81 ₹234.35 ₹169.7 ₹63.93 ₹155.99 -7%
◆ best value in the comp set per metric · Δ = subject vs average of the other companies.
« ‹ › » Latest: FY26 · Consolidated CHART » ALPHA AI » COMP » FA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95% .
